KEYTRUDA Padcev MIBC Survival: New Era in Treat...

By HEOR Staff Writer

March 2, 2026

KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Genotype ECG Prediction
Transformative PBM Reform Legislation Signed into Law
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Launch of TrumpRx Drug Pricing: Savings on Essential Medications